You can buy or sell ATXI and other stocks, options, ETFs, and crypto commission-free!
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. Read More The company was founded on February 9, 2015 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Yahoo FinanceMay 13
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
Safety study completed; Expect to report data from 2nd pivotal Phase 3 trial by the end of second quarter 2019 NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2019. “We recently completed the safety study for IV tramadol and expect to report data by the end of this quarter fr...
Guru FocusApr 30
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. ( ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of Directors. “Tom’s breadth and depth of operational and commercial experience, which includes leadership in the acute care pharmaceutical business, will be a significant asset to Avenue,” said Dr. Lindsay Rosenwald, Avenue’s Exec...
-$0.43 per share
-$0.82 per share